Clinical and regional distribution of TTN variants in toe walking: A descriptive cohort study

David Pomarino , Amel Sidi Athmane , Bastian Fregien , Alexander Nazarkin , Kevin M. Rostásy

Global Medical Genetics ›› 2026, Vol. 13 ›› Issue (02) : 100112

PDF (1579KB)
Global Medical Genetics ›› 2026, Vol. 13 ›› Issue (02) :100112 DOI: 10.1016/j.gmg.2026.100112
Research article
research-article
Clinical and regional distribution of TTN variants in toe walking: A descriptive cohort study
Author information +
History +
PDF (1579KB)

Abstract

Background:The TTN gene encodes titin, a key structural protein of the sarcomere. Variants in TTN are frequently identified in genetic testing, but their clinical interpretation remains challenging due to their high prevalence in the general population and frequent classification as variants of uncertain significance (VUS). Toe walking is often considered idiopathic; however, emerging evidence suggests a potential genetic contribution. Objective:To provide a descriptive analysis of TTN variants in children presenting with persistent toe walking, using a region-based approach to explore variant distribution and associated clinical features. Methods:This retrospective study included children with persistent toe walking following exclusion of known neurological, neuromuscular, and orthopedic causes. All patients underwent standardized clinical assessment and targeted next-generation sequencing using a 49-gene panel. TTN variants were grouped into predefined cDNA intervals (c.1–c.9000). Clinical and genetic data were analyzed descriptively. Results:Fifty-five patients carrying 43 TTN variants were included (mean age 7.3 years; 71% male). Variants were unevenly distributed, with clustering in the c.1001–2000 (22.4%) and c.3001–4000 (19.0%) regions. All variants were classified as VUS. A consistent clinical phenotype was observed across groups, including persistent toe walking, reduced ankle dorsiflexion, and a frequent positive foot drop test. Group-specific differences were noted but remained inconsistent and descriptive. Conclusions: TTN variants in children with toe walking show heterogeneous distribution but a largely consistent clinical presentation. No clear genotype–phenotype correlation was identified. These findings highlight the need for cautious interpretation of TTN VUS and further studies to clarify their clinical significance.

Keywords

Genetic Testing / Toe Walking / Neurology / Pediatrics / TTN

Cite this article

Download citation ▾
David Pomarino, Amel Sidi Athmane, Bastian Fregien, Alexander Nazarkin, Kevin M. Rostásy. Clinical and regional distribution of TTN variants in toe walking: A descriptive cohort study. Global Medical Genetics, 2026, 13 (02) : 100112 DOI:10.1016/j.gmg.2026.100112

登录浏览全文

4963

注册一个新账户 忘记密码

Acknowledgments

We extend our sincere gratitude to the children and their families whose participation made this study possible. We also thank the medical professionals involved for their expert clinical assessments, thoughtful project oversight, and constructive feedback throughout the course of this research. We are particularly grateful to the administrative, technical, and support staff at Pomarino Praxis für Ganganomalien in Hamburg for their careful data acquisition and coordination of the study. We further acknowledge Labor Dr. Heidrich & Colleagues for providing specialized genetic testing and expert analytical support.

Funding Statement

This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Ethical statement

This study was conducted in accordance with the ethical principles of the World Medical Association Declaration of Helsinki. All procedures were performed in compliance with relevant laws and institutional guidelines and were approved by the ethical board of the Deutschen Verbandes für Physiotherapie an der Physio-Akademie in Wremen, Germany (project number 2025–02). Prior to participation, written informed consent was obtained from all subjects. The consent process included explanations of the study’s purpose, procedures, and any potential implications of the results. All data collected were formally anonymized to protect participant confidentiality. This manuscript was prepared in accordance with the International Committee of Medical Journal Editors (ICMJE) recommendations.

CRediT authorship contribution statement

David Pomarino contributed to the conceptualization of the study, data curation, and formal analysis. Amel Sidi Athmane contributed to data curation and investigation and drafted the original manuscript. Bastian Fregien and Alexander Nazarkin contributed to the study methodology and validation. Kevin M. Rostásy contributed to formal analysis, supervision, validation, and manuscript review and editing. All authors reviewed and approved the final manuscript.

Data availability

Raw next-generation sequencing data were generated as part of routine clinical diagnostics and are not publicly available because of ethical, privacy, and institutional restrictions governing human genetic data. De-identified variant-level data supporting the findings of this study are provided in Supplementary Table 2. Additional anonymized data may be made available from the corresponding author upon reasonable request and subject to ethical approval.

Declaration of Competing Interest

The Authors declare that there is no conflict of interest.

Declaration of Generative AI and AI-assisted technologies in the writing process

Generative AI Deepseek was used in the writing phase of this manuscript exclusively for linguistic polishing and enhancing clarity. All scientific reasoning, data analysis, and intellectual substance remain the sole contribution of the authors. The AI was not employed in the research process itself.

References

[1]

H.L. Granzier, S. Labeit, Discovery of Titin and Its Role in Heart Function and Disease, Circ. Res. 136 (1) (2025) 135-157, https://doi.org/10.1161/CIRCRESAHA.124.323051

[2]

M. Gigli, R.L. Begay, G. Morea, et al., A Review of the Giant Protein Titin in Clinical Molecular Diagnostics of Cardiomyopathies, 21. Published 2016 Jul 21, Front. Cardiovasc. Med. 3 (2016), https://doi.org/10.3389/fcvm.2016.00021

[3]

National Center for Biotechnology Information (NCBI), TTN (titin) [Internet] ([cited), National Library of Medicine (US), Bethesda (MD), 2026https://www.ncbi.nlm.nih.gov/gene/7273〉([cited).

[4]

C.A. Tharp, M.E. Haywood, O. Sbaizero, M.R.G. Taylor, L. Mestroni, The Giant Protein Titin’s Role in Cardiomyopathy: Genetic, Transcriptional, and Post—translational Modifications of TTN and Their Contribution to Cardiac Disease, Published 2019 Nov 28. Front. Physiol. 10 (2019) 1436, https://doi.org/10.3389/fphys.2019.01436

[5]

J. Gohlke, J. Lindqvist, Z. Hourani, et al., Pathomechanisms of Monoallelic variants in TTN causing skeletal muscle disease, Hum. Mol. Genet. 33 (23) (2024) 2003-2023, https://doi.org/10.1093/hmg/ddae136

[6]

M. Gigli, R.L. Begay, G. Morea, et al., A Review of the Giant Protein Titin in Clinical Molecular Diagnostics of Cardiomyopathies, 21. Published 2016 Jul 21, Front. Cardiovasc. Med. 3 (2016), https://doi.org/10.3389/fcvm.2016.00021

[7]

D. Pomarino, A. Sidi Athmane, B. Fregien, A. Nazarkin, K.M. Rostásy, Pediatric toe—walking cohort with heterozygous SBF1 variants: A phenotypic description, Published 2026 Feb 13. Glob. Med. Genet. 13 (1) (2026) 100095, https://doi.org/10.1016/j.gmg.2026.100095

[8]

D. Pomarino, K.M. Rostásy, B. Fregien, J.O. Schönfeldt, A. Nazarkin, Persistent toe walking as a prominent feature in pediatric PMP22—Related neuropathies: A retrospective cohort study, Published 2025 Dec 3. Glob. Med. Genet. 12 (4) (2025) 100082, https://doi.org/10.1016/j.gmg.2025.100082

[9]

D. Pomarino, B. Fregien, K.M. Rostásy, Clinical Features in Children with Persistent Toe Walking Who Carry Heterozygous PYGM Variants: A Cross—Sectional Study, J. Musculoskelet. Neuron Interact. 26 (1) (2026) 115-123, https://doi.org/10.22540/JMNI—26—115

PDF (1579KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/